MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-20-2023
Baudax Bio Cash Conversion Cycle 2011-2026 | BXRX
Annual Cash Conversion Cycle Baudax Bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.3 | 314 | -104 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 314 | -104 | 64.9 |
Quarterly Cash Conversion Cycle Baudax Bio
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.5 K | -4.24 K | -793 | - | 294 | 707 | 509 | - | 496 | 329 | 103 | - | -45.6 | -81.4 | 28.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 707 | -14.5 K | -1.43 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.29 | -1.98 % | $ 2.56 B |  USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.8 | -5.29 % | $ 4.36 M |  China |
 |
Axsome Therapeutics
AXSM
|
-256 | $ 166.62 | 0.14 % | $ 8.29 B | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.76 | -1.7 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
-48.2 | $ 0.97 | -5.15 % | $ 71.2 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-6 K | $ 3.15 | -5.69 % | $ 1.13 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
735 | $ 28.45 | -2.57 % | $ 1.65 B | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
-32.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-15.9 | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-839 | $ 3.65 | -3.95 % | $ 116 M |  France |
 |
Alector
ALEC
|
-13.8 | $ 2.1 | -5.2 % | $ 216 M | USA |
 |
Altimmune
ALT
|
15.1 K | $ 4.16 | -0.12 % | $ 295 M | USA |
 |
Teligent, Inc.
TLGT
|
120 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
139 | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
120 | $ 23.99 | 0.46 % | $ 2.93 B | USA |
 |
Amarin Corporation plc
AMRN
|
213 | $ 13.89 | -0.32 % | $ 5.76 B |  Irlanda |
 |
AbbVie
ABBV
|
284 | $ 231.88 | -1.0 % | $ 410 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
254 | - | - | $ 8.14 B | USA |
 |
AIM ImmunoTech
AIM
|
46 | $ 0.71 | -8.96 % | $ 34.1 M | USA |